JP2019524131A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524131A5 JP2019524131A5 JP2019507161A JP2019507161A JP2019524131A5 JP 2019524131 A5 JP2019524131 A5 JP 2019524131A5 JP 2019507161 A JP2019507161 A JP 2019507161A JP 2019507161 A JP2019507161 A JP 2019507161A JP 2019524131 A5 JP2019524131 A5 JP 2019524131A5
- Authority
- JP
- Japan
- Prior art keywords
- strain
- poxvirus
- nucleic acid
- vaccinia virus
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 21
- 241000700618 Vaccinia virus Species 0.000 claims 19
- 230000001093 anti-cancer Effects 0.000 claims 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 7
- 241000283690 Bos taurus Species 0.000 claims 5
- 241000191927 Rabbitpox virus Utrecht Species 0.000 claims 5
- 241000700646 Vaccinia virus WR Species 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 241000700635 Orf virus Species 0.000 claims 3
- 108700039887 Essential Genes Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 244000309459 oncolytic virus Species 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 108010013351 sodium-iodide symporter Proteins 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022017693A JP7395628B2 (ja) | 2016-08-09 | 2022-02-08 | キメラポックスウイルス組成物及びその使用 |
| JP2023200433A JP7631485B2 (ja) | 2016-08-09 | 2023-11-28 | キメラポックスウイルス組成物及びその使用 |
| JP2025016649A JP2025072482A (ja) | 2016-08-09 | 2025-02-04 | キメラポックスウイルス組成物及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662372408P | 2016-08-09 | 2016-08-09 | |
| US62/372,408 | 2016-08-09 | ||
| US201762519010P | 2017-06-13 | 2017-06-13 | |
| US62/519,010 | 2017-06-13 | ||
| PCT/US2017/046163 WO2018031694A1 (en) | 2016-08-09 | 2017-08-09 | Chimeric poxvirus compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022017693A Division JP7395628B2 (ja) | 2016-08-09 | 2022-02-08 | キメラポックスウイルス組成物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524131A JP2019524131A (ja) | 2019-09-05 |
| JP2019524131A5 true JP2019524131A5 (OSRAM) | 2020-09-17 |
| JP7023929B2 JP7023929B2 (ja) | 2022-02-22 |
Family
ID=61163330
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019507161A Active JP7023929B2 (ja) | 2016-08-09 | 2017-08-09 | キメラポックスウイルス組成物及びその使用 |
| JP2022017693A Active JP7395628B2 (ja) | 2016-08-09 | 2022-02-08 | キメラポックスウイルス組成物及びその使用 |
| JP2023200433A Active JP7631485B2 (ja) | 2016-08-09 | 2023-11-28 | キメラポックスウイルス組成物及びその使用 |
| JP2025016649A Pending JP2025072482A (ja) | 2016-08-09 | 2025-02-04 | キメラポックスウイルス組成物及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022017693A Active JP7395628B2 (ja) | 2016-08-09 | 2022-02-08 | キメラポックスウイルス組成物及びその使用 |
| JP2023200433A Active JP7631485B2 (ja) | 2016-08-09 | 2023-11-28 | キメラポックスウイルス組成物及びその使用 |
| JP2025016649A Pending JP2025072482A (ja) | 2016-08-09 | 2025-02-04 | キメラポックスウイルス組成物及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12084687B2 (OSRAM) |
| EP (1) | EP3497209A4 (OSRAM) |
| JP (4) | JP7023929B2 (OSRAM) |
| KR (3) | KR20250067190A (OSRAM) |
| CN (3) | CN118853594A (OSRAM) |
| AU (2) | AU2017311380A1 (OSRAM) |
| BR (1) | BR112019002646A2 (OSRAM) |
| CA (1) | CA3033512A1 (OSRAM) |
| MX (1) | MX2019001672A (OSRAM) |
| RU (2) | RU2757002C2 (OSRAM) |
| WO (1) | WO2018031694A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014100615A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| JP2018510143A (ja) | 2015-02-25 | 2018-04-12 | メモリアル スローン ケタリング キャンサー センター | 不活化非複製改変ワクシニアウイルスアンカラ（ｍｖａ）の固形腫瘍のための単独療法又は免疫チェックポイント遮断剤併用における使用 |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| BR112018016948A2 (pt) | 2016-02-25 | 2019-01-08 | Memorial Sloan Kettering Cancer Center | mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos |
| EP3419648A4 (en) | 2016-02-25 | 2019-09-11 | Memorial Sloan-Kettering Cancer Center | REPLICATING COMPETENTES WEAKENED VACCINIA VIRUSES WITH DELETION OF THYMIDINE KINASE WITH AND WITHOUT EXPRESSION OF HUMAN FLT3L OR GM-CSF FOR CANCER IMMUNOTHERAPY |
| US12144850B2 (en) | 2016-04-08 | 2024-11-19 | Purdue Research Foundation | Methods and compositions for car T cell therapy |
| CA3033512A1 (en) * | 2016-08-09 | 2018-02-15 | City Of Hope | Chimeric poxvirus compositions and uses thereof |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| US11242509B2 (en) | 2017-05-12 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| CN111163803B (zh) * | 2017-08-11 | 2025-05-09 | 希望之城公司 | 表达car t细胞靶物的溶瘤病毒及其用途 |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| JP2021516957A (ja) * | 2018-03-07 | 2021-07-15 | トランジェーヌＴｒａｎｓｇｅｎｅ | パラポックスウイルスベクター |
| WO2019213173A1 (en) * | 2018-04-30 | 2019-11-07 | City Of Hope | Neural stem cell compositions including chimeric poxviruses for cancer treatment |
| US12252702B2 (en) | 2018-09-15 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| CN113583977B (zh) * | 2020-04-30 | 2025-06-06 | 杭州康万达医药科技有限公司 | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 |
| GB2614309A (en) | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
| WO2023213763A1 (en) * | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| JP2025528219A (ja) | 2022-08-18 | 2025-08-26 | トランジェーヌ | キメラポックスウイルス |
| AU2024280931A1 (en) * | 2023-05-26 | 2025-11-27 | Probiogen Ag | Rapid selection system for the generation of recombinant enveloped viruses |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
| CN120718864B (zh) * | 2025-08-28 | 2025-11-28 | 山东农业大学 | 一种高度不成熟鸭坦布苏病毒及其培养方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT406376B (de) * | 1998-01-16 | 2000-04-25 | Immuno Ag | Chimäres poxvirus enthaltend eine retrovirale vektorkomponente |
| JP2003528605A (ja) | 2000-03-28 | 2003-09-30 | ユニヴァーシティー オヴ ロチェスター | ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法 |
| EA012723B1 (ru) * | 2002-11-25 | 2009-12-30 | Бавариан Нордик А/С | Рекомбинантный поксвирус, содержащий по меньшей мере два промотора ati вируса коровьей оспы, и его применение |
| AU2004289953B2 (en) * | 2003-06-18 | 2008-09-25 | Genelux Corporation | Modified recombinant vaccina viruses and other microorganisms, uses thereof |
| US20090098529A1 (en) | 2006-10-16 | 2009-04-16 | Nanhai Chen | Methods for attenuating virus strains for diagnostic and therapeutic uses |
| DK2212423T3 (en) * | 2007-11-19 | 2015-03-16 | Transgene Sa | oncolytic poxvirus vectors |
| CA2795695A1 (en) * | 2010-04-09 | 2011-10-13 | The University Of Tokyo | Microrna-controlled recombinant vaccinia virus and use thereof |
| ES2733211T3 (es) | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| CN104768567B (zh) | 2012-05-18 | 2017-07-11 | 奥塔哥创业有限公司 | 用于伤口愈合的联合治疗和组合物 |
| US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| CA3033512A1 (en) * | 2016-08-09 | 2018-02-15 | City Of Hope | Chimeric poxvirus compositions and uses thereof |
-
2017
- 2017-08-09 CA CA3033512A patent/CA3033512A1/en active Pending
- 2017-08-09 CN CN202410528631.4A patent/CN118853594A/zh active Pending
- 2017-08-09 RU RU2019106319A patent/RU2757002C2/ru active
- 2017-08-09 KR KR1020257014373A patent/KR20250067190A/ko active Pending
- 2017-08-09 EP EP17840232.7A patent/EP3497209A4/en active Pending
- 2017-08-09 CN CN201780062335.8A patent/CN110199018B/zh active Active
- 2017-08-09 RU RU2021128158A patent/RU2021128158A/ru unknown
- 2017-08-09 CN CN202410528486.XA patent/CN118834840A/zh active Pending
- 2017-08-09 US US16/324,541 patent/US12084687B2/en active Active
- 2017-08-09 KR KR1020237024342A patent/KR20230113832A/ko not_active Ceased
- 2017-08-09 KR KR1020197006987A patent/KR102557818B1/ko active Active
- 2017-08-09 MX MX2019001672A patent/MX2019001672A/es unknown
- 2017-08-09 WO PCT/US2017/046163 patent/WO2018031694A1/en not_active Ceased
- 2017-08-09 BR BR112019002646-0A patent/BR112019002646A2/pt active IP Right Grant
- 2017-08-09 AU AU2017311380A patent/AU2017311380A1/en not_active Abandoned
- 2017-08-09 JP JP2019507161A patent/JP7023929B2/ja active Active
-
2022
- 2022-02-08 JP JP2022017693A patent/JP7395628B2/ja active Active
-
2023
- 2023-11-20 AU AU2023270200A patent/AU2023270200A1/en active Pending
- 2023-11-28 JP JP2023200433A patent/JP7631485B2/ja active Active
-
2024
- 2024-07-17 US US18/776,109 patent/US20250084384A1/en active Pending
-
2025
- 2025-02-04 JP JP2025016649A patent/JP2025072482A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524131A5 (OSRAM) | ||
| JP2022065034A5 (OSRAM) | ||
| JP2025072482A5 (OSRAM) | ||
| JP2024026191A5 (OSRAM) | ||
| RU2019106319A (ru) | Композиции химерного поксвируса и их применение | |
| JP2015533841A5 (OSRAM) | ||
| Mizuno et al. | Novel haloarchaeal viruses from Lake Retba infecting Haloferax and Halorubrum species | |
| JP2012509340A5 (OSRAM) | ||
| JP2013507935A5 (OSRAM) | ||
| CN104762321A (zh) | 基于CRISPR/Cas9系统靶向敲除KHV基因的敲除载体构建方法及其crRNA原件 | |
| EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
| BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
| JP2015533297A5 (OSRAM) | ||
| JP2011155981A5 (OSRAM) | ||
| Jeong et al. | Characterization of the DNA nucleotide sequences in the genome of red sea bream iridoviruses isolated in Korea | |
| CN110944675A (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| JP2017524348A5 (OSRAM) | ||
| Murata et al. | Characterization of Meq proteins from field isolates of Marek’s disease virus in Japan | |
| Peng et al. | Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells | |
| JP2013523718A5 (OSRAM) | ||
| JP2013538554A5 (OSRAM) | ||
| JP2019500907A5 (OSRAM) | ||
| MX2024002641A (es) | Uso de micro ácido ribonucleico (arn) para la regulación por disminución de la expresión de transgenes citotóxicos mediante el virus vaccinia ankara modificado (mva). | |
| Chen et al. | Molecular evidence and sequence analysis of a natural reassortant between Cucumber mosaic virus subgroup IA and II strains | |
| JP2014530609A5 (OSRAM) |